Stockscreener 앱 받기
12.61
7.96%
0.93
시간 외 거래:
12.61
전일 마감가:
$11.68
열려 있는:
$12.195
하루 거래량:
43,715
Relative Volume:
0.55
시가총액:
$20.46M
수익:
-
순이익/손실:
$-3.34M
주가수익비율:
-4.6712
EPS:
-2.6995
순현금흐름:
$-10.54M
1주 성능:
-11.38%
1개월 성능:
+0.96%
6개월 성능:
+92.81%
1년 성능:
-97.69%
1일 변동 폭
$11.40
$12.99
1주일 범위
$10.67
$14.25
52주 변동 폭
$2.88
$2,235.00
Polyrizon Ltd Stock (PLRZ) Company Profile
Compare PLRZ vs VRTX, REGN, ARGX, ALNY, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PLRZ
Polyrizon Ltd
|
12.61 | 18.95M | 0 | -3.34M | -10.54M | -2.6995 |
VRTX
Vertex Pharmaceuticals Inc
|
447.26 | 113.44B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
777.25 | 81.68B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
743.12 | 45.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.73 | 43.88B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
164.86 | 35.25B | 606.42M | -1.28B | -997.58M | -6.403 |
Polyrizon Ltd 주식(PLRZ)의 최신 뉴스
Polyrizon (PLRZ) CEO sells 500 shares in open-market trade - Stock Titan
Carmel Liron of Polyrizon (PLRZ) sells 942 shares, holds 3,127 - Stock Titan
Polyrizon (PLRZ) director sells 3,292 shares, retains 19,850 total - Stock Titan
Patterns Watch: Can Polyrizon Ltd beat the S P 500Entry Point & Expert Curated Trade Ideas - baoquankhu1.vn
Top Polyrizon Insiders Quietly Cash Out in Notable Stock Moves - TipRanks
Director at Polyrizon (PLRZ) sells 100 shares, retains 4,069 - Stock Titan
Polyrizon (PLRZ) CEO sells 3,900 shares, holding 32,012 afterward - Stock Titan
Polyrizon (PLRZ) CTO trims stake with 2,917-share open-market sale - Stock Titan
VIX Spike: Can Polyrizon Ltd disrupt its industryGDP Growth & Growth Focused Entry Reports - baoquankhu1.vn
We're Keeping An Eye On Polyrizon's (NASDAQ:PLRZ) Cash Burn Rate - simplywall.st
US Market Wrap: Will Polyrizon Ltd outperform its industry peersWeekly Trend Recap & Risk Managed Investment Signals - baoquankhu1.vn
Polyrizon (PLRZ) updates 20-F, outlines $464,000 cyber fraud response - Stock Titan
Polyrizon reports $17.5M cash position, advances FDA discussions By Investing.com - Investing.com South Africa
Polyrizon reports $17.5M cash position, advances FDA discussions - Investing.com
Polyrizon Provides 2025 and Recent Highlights - manilatimes.net
Polyrizon pushes allergy and viral nasal blockers toward U.S. trials - Stock Titan
Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025 - The Manila Times
Polyrizon (PLRZ) 20-F: deepening losses, cash position and high biotech risks - Stock Titan
Polyrizon signs MOU to acquire 20% stake in drone maker Colugo - Investing.com Australia
Polyrizon signs MOU to acquire up to 20% stake in eVTOL firm Colugo - msn.com
Polyrizon Intends to Acquire up to 20% Stake in Colugo, Developer of Advanced eVTOL Drones for Defense and Urban Air Mobility Applications - manilatimes.net
Why a nasal drug developer wants a stake in an Israeli eVTOL drone maker - Stock Titan
Insider Sell: Does Polyrizon Ltd offer margin of safety2026 Valuation Update & Long-Term Growth Portfolio Plans - baoquankhu1.vn
Market Trends: Will Polyrizon Ltd stock hit new highs in YEAR2026 Buyback Activity & Stepwise Trade Execution Plans - baoquankhu1.vn
Polyrizon (PLRZ) CTO details initial share and option holdings - Stock Titan
[Form 3] Polyrizon Ltd. Initial Statement of Beneficial Ownership - Stock Titan
Polyrizon (PLRZ) Chief Science Officer reports share and option holdings - Stock Titan
Director Itzhaik Asaf details restricted share holdings at Polyrizon (PLRZ) - Stock Titan
Polyrizon (PLRZ) director discloses initial restricted share holdings - Stock Titan
Polyrizon (PLRZ) director discloses vested and restricted share holdings - Stock Titan
Carmel Liron details Polyrizon (PLRZ) restricted share ownership and vesting - Stock Titan
Polyrizon (PLRZ) CEO Tomer Izraeli details initial share and option holdings - Stock Titan
Polyrizon (PLRZ) CFO details initial share and option holdings - Stock Titan
Polyrizon signs CRO agreement for biocompatibility studies By Investing.com - in.investing.com
Polyrizon signs CRO agreement for biocompatibility studies - Investing.com
Polyrizon Taps Global CRO to Run Key Preclinical Safety Studies Ahead of First Clinical Trials - TipRanks
Polyrizon Signs an Agreement with Leading Global Preclinical CRO as Part of Clinical Development Program - The Manila Times
Polyrizon (PLRZ) signs global CRO pact to advance nasal hydrogel trials - Stock Titan
Nasal allergy startup Polyrizon readies human trials with safety tests - Stock Titan
Eli Zamir reports ≤5% stake in Polyrizon Ltd. (PLRZ) via Schedule 13G - Stock Titan
Polyrizon (PLRZ) Institutional Ownership 2026 - MarketBeat
Polyrizon Announces GMP Manufacturing of Clinical Trial Material with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical Study - marketscreener.com
Polyrizon completes GMP batch for intranasal product trial By Investing.com - Investing.com South Africa
Aug Intraday: Does Polyrizon Ltd have strong fundamentalsRate Hike & AI Optimized Trade Strategies - baoquankhu1.vn
Polyrizon Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO AmatsiAquitaine S.A.S for Planned U.S. Clinical Study - Bitget
Polyrizon completes GMP batch for intranasal product trial - Investing.com India
Polyrizon Completes GMP Clinical Material for Planned U.S. Intranasal Study - TipRanks
Polyrizon (Nasdaq: PLRZ) makes GMP CTM for planned U.S. study - Stock Titan
Polyrizon Announces GMP Manufacturing of Clinical Trial Material (CTM) with Eurofins CDMO ... - Caledonian Record
Polyrizon makes GMP batch for planned U.S. nasal allergy, virus trial - Stock Titan
PLRZ Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Polyrizon Ltd (PLRZ) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.52%
0.51%
자본화:
|
볼륨(24시간):